Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProCID: Panzyga Dosing in CIDP
NCT02638207Phase 3Completed
- Sponsor
- Octapharma
- Start
- Sep 2017
- Primary completion
- Sep 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
A Phase 3 trial of intravenous immunoglobulin G in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by Octapharma. Started Sep 2017; status: completed.
02
Drugs
intravenous immunoglobulin G
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT02638207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02638207.